PCVX
Vaxcyte, Inc.
NASDAQ · Healthcare · Biotechnology · US
$61.25
+0.13%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | — | — | — | — | — |
| Cost of Revenue | 865.0K | — | — | — | — |
| Gross Profit | (865.0K) | — | — | — | — |
| Operating Expenses | |||||
| R&D Expense | 1.0B | 794.3M | 476.6M | 332.3M | 169.5M |
| SG&A Expense | 132.7M | 129.4M | 92.9M | 60.7M | 39.8M |
| General & Admin Expense | 132.7M | 129.4M | 92.9M | 60.7M | 39.8M |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | (865.0K) | — | — | 75.0M | 23.0M |
| Total Operating Expenses | 1.2B | 923.7M | 569.5M | 468.0M | 232.3M |
| Cost and Expenses | 1.2B | 923.7M | 569.5M | 468.0M | 232.3M |
| Operating Income (EBIT) | (1.2B) | (923.7M) | (569.5M) | (468.0M) | (232.3M) |
| Non-Operating | |||||
| Interest Income | 108.1M | 119.7M | 110.0M | 62.9M | 8.4M |
| Interest Expense | — | — | — | — | 2.0K |
| Net Interest Income | 108.1M | 119.7M | 110.0M | 62.9M | 8.4M |
| Other Non-Op Income/Expense | 101.0M | 157.0M | 105.6M | 65.8M | 8.8M |
| Non-Operating Income (excl Interest) | (89.8M) | (157.0M) | (105.6M) | (65.8M) | (8.8M) |
| EBT (Pre-Tax Income) | (1.1B) | (766.6M) | (463.9M) | (402.3M) | (223.5M) |
| Income Tax Expense | — | — | — | — | — |
| Bottom Line | |||||
| Net Income | (1.1B) | (766.6M) | (463.9M) | (402.3M) | (223.5M) |
| Earnings from Cont. Ops | (1.1B) | (766.6M) | (463.9M) | (402.3M) | (223.5M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (1.1B) | (766.6M) | (463.9M) | (402.3M) | (223.5M) |
| Per Share | |||||
| Basic EPS | ($7.64) | ($5.63) | ($3.80) | ($4.14) | ($3.44) |
| Diluted EPS | ($7.64) | ($5.63) | ($3.80) | ($4.14) | ($3.44) |
| Revenue Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Shares | |||||
| Basic Shares Outstanding | 144.5M | 136.1M | 122.0M | 97.2M | 64.9M |
| Diluted Shares Outstanding | 144.5M | 136.1M | 122.0M | 97.2M | 64.9M |
| Profitability Metrics | |||||
| EBITDA | (1.1B) | (741.8M) | (448.1M) | (392.1M) | (214.0M) |
| D&A | 23.9M | 24.9M | 15.8M | 10.2M | 9.5M |
| EBIT | (1.1B) | (766.6M) | (463.9M) | (402.3M) | (223.5M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026